Outram Bio

Outram Bio targets early-stage life sciences and biotechnology companies, primarily at the startup and Series A stages. The firm's mandate covers drug discovery, platform technologies, and therapeutic development. This singular focus on biotech distinguishes it from generalist technology and healthcare funds active in Asia.

Outram Bio's mandate is narrowly focused on biotechnology and life sciences. Public information does not indicate the firm evaluates opportunities in consumer technology, fintech, enterprise software, real estate, or other non-healthcare verticals. Its exclusion profile is driven by sector concentration rather than an explicit avoidance list.